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DIABETES
PD1
COMPLIANCE WITH AMERICAN DIABETIC 
ASSOCIATION (ADA) RECOMMENDATIONS IN 
A TYPE 2 DIABETIC POPULATION IN AN 
ACADEMIC FAMILY MEDICINE CENTER
Taylor AT1, Longe RL1, Wagner PJ2
1University of Georgia, Athens, GA, US; 2Medical College of 
Georgia, Augusta, GA, US
OBJECTIVES: To characterize the population, measure
compliance with ADA recommendations, and categorize
medication usage.
METHODS: All type 2 diabetics (N  116) visiting a
family medicine center during January 1997 as recorded
in an electronic medical record were included. Recom-
mendations for “continuing care visits” were the key data
elements retrospectively reviewed for a 1-year period
(January–December 1997). Demographic, health insur-
ance, routine office visit (e.g., weight, blood pressure, eye
and foot exams), dietary and exercise planning, disease
monitoring (e.g., self blood glucose monitoring, serum
glycated hemoglobin, serum cholesterol, urinalysis), and
detailed drug usage data were collected.
RESULTS: The sample had a mean age of 61.1 years,
was 53.4% African American and 44.8% Caucasian, and
was 69.0% female. A government-financed health insur-
ance plan insured most patients (71.5%). On the average,
a patient had about eight office visits annually. Agree-
ment with ADA recommendations of weight and blood
pressure measurements at each visit was observed in 56.0%
and 78.4% of the patients respectively. Most patients did
not have annual primary care eye (57.8%) or dilated oph-
thalmic (42.2%) or foot (73.3%) examinations docu-
mented. Agreement with laboratory recommendations
was as follows: annual total cholesterol: 59.5%; semian-
nual glycated hemoglobin: 14.7%; and annual urinalysis:
66.4%. Most patients (92) were treated with a single
drug; 23 of 116 patients used two drugs. Glyburide and
glypizide were prescribed most frequently. Compliance
with recommendations increased with age and in patients
receiving multiple versus single or no drug therapy.
CONCLUSION: Documentation of current practice
shows wide variation from ADA recommendations for
type 2 diabetics. Interventions to modify documentation
are planned.
INFECTIOUS DISEASE
PID1
COST-EFFECTIVENESS OF LEVOFLOXACIN 
VERSUS CLARITHROMYCIN IN PATIENTS 
EVALUABLE FOR CLINICAL EFFICACY IN THE 
TREATMENT OF ACUTE BACTERIAL SINUSITIS
Rance L1, Dornsief B2
1Janssen-Ortho Inc., Toronto, Canada; 2Advanced Biologics, 
Lambertville, NJ, US
OBJECTIVE: Resource utilization and cost-effectiveness
data were compared in patients taking 500 mg od (AM)
levofloxacin (levo) with that of 500 mg bid clarithromy-
cin for up to 14 days.
METHODS: Patients were eligible for this multicenter,
double-blind study if they had signs and symptoms of
acute sinusitis, including X-ray evidence. Clinical response
was evaluated 2–5 days after completion of therapy and
at 1 month post therapy. Utilization parameters were de-
termined from the cost of drug, cost of the physician’s of-
fice or emergency room visit, and costs of concomitant
medications. The total cost of resources and average cost
per patient was calculated. The cost-effectiveness ratio
was determined by taking the average cost of product di-
vided by the proportion of clinical success as assessed by
investigator. The incremental cost-effectiveness ratio is
the mean cost per levo patient minus the mean cost per
clarithromycin patient, divided by the proportion of clini-
cal success of levo minus the proportion of clinical suc-
cess of clarithromycin. Cost-minimization was calculated
from the mean cost per levo patient minus the mean cost
per clarithromycin patient.
RESULTS: 191 patients had resource utilization data, 98
in the levo group and 93 in the clarithromycin group. The
total cost of resources was $11,566.24 for levo and
$12,635.14 for clarithromycin. Average cost per patient
was $119.24 for levo and $135.86 for clarithromycin. The
cost-effectiveness ratio for levo was 1.3, and for clarithro-
mycin 1.5. Because clinical success rates were similar a
cost minimization analysis was performed. The result was
16.6. The incremental cost-effectiveness ratio was 	50.5.
CONCLUSION: In patients with similar clinical success
rates, this study shows that levo 500 mg od is more cost-
effective than 500 mg bid clarithromycin.
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OF PATIENTS WITH LOCAL
APPENDICULAR PERITONITIS
Rozenson O1, Bazganov N2, Belkov A1, Bikov A3, 
Stratchounski L1
1Smolensk State Medical Academy, Smolensk, Russia; 
2Yaroslavlskya State Medical Academy, Yaroslavl, Russia; 
3Volgogradskaya State Medical Academy, Volgograd, Russia
Abstracts 31
OBJECTIVES: Pharmacoeconomic assessment of cefa-
mandole/tobramycin (CT) versus standard therapy (ST)
in the treatment of local appendicular peritonitis (LAP).
Standard therapy was antibacterial drugs routinely used
for treatment of LAP in centers of study. It was allowed
to add metronidazole to both regimes.
METHODS: Clinical outcomes and health resource utili-
zation data were collected from 92 patients enrolled in an
open, comparative, randomized, prospective, multicenter
trial comparing the efficacy and safety of CT versus ST in
the treatment of LAP. A cost-minimization analysis was
performed from the institutional perspective. Costs of
study antibiotics, treatment of failures and adverse events
(AE), and hospitalization were calculated.
RESULTS: The most common regimes in ST were ampi-
cillin (27%), ampicillin 
 oxacillin (11%), penicillin 

gentamicin (9%), penicillin 
 kanamycin (9%). Metron-
idazole was used in five patients in CT and in four pa-
tients in ST. Cure rates were 42 of 44 (95.5%) for CT
and 41 of 45 (91.1%) for ST (p  1.000). Adverse events
(AE) were 12 of 47 (25.5%) for CT and 10 of 45
(22.2%) for ST (p  0.547). Three levels of cost were an-
alyzed: level I  study drug acquisition cost; level II 
level I 
 preparation/administration 
 treatment of AE/
failures 
 hospital bed costs; level III  level II 	 level I.
CONCLUSIONS: ST was cost-effective compared to CT
in the treatment of LAP. The pharmacoeconomic advan-
tage of ST was due to the significantly lower acquisition
cost of ST antibiotics.
MENTAL HEALTH AND
NEUROLOGIC DISORDERS
PMH1
ANNUAL DIRECT COSTS OF PSYCHOTROPIC 
MEDICATIONS FOR THE TREATMENT OF 
PSYCHIATRIC DISORDERS IN INDIA
Chaturvedi SK
National Institute of Mental Health & Neurosciences, 
Bangalore, India
OBJECTIVES: The present study ascertains the annual
direct costs of common psychotropic medications used in
the management of common psychiatric disorders in a
country with limited financial resources.
METHODS: The direct costs of the psychopharmacologi-
cal agents evaluated were antidepressants (tricyclic, SSRI,
and newer antidepressants available); antipsychotics (phe-
nothiazines, butrophenones, and atypical antipsychotics);
benzodiazepines and sedatives. The annual direct costs of
the medications were ascertained from the recent monthly
index for medical specialties (MIMS), from standard
chemists, and from pharmaceutical firms. The statistical
mode or most frequent cost was considered for further
computations. 
RESULTS: Regarding antidepressants, tricyclics were
noted to have the following annual costs (1 US$  Rs.
43): Imipramine Rs. 1130 (US $26.3), amitriptyline Rs.
1460 ($34), dothiepin Rs. 2410 ($56.1), trimipramine
Rs. 2430 ($56.5) and clomipramine Rs. 6130 ($142.6).
Fluoxetine has an annual cost of Rs. 840 ($19.5), mi-
anserin Rs. 2010 ($46.7), amoxapine Rs. 3835 ($89.1),
amineptine Rs. 10,700 ($248.8), and the most expensive,
tianeptine, Rs. 21,000 ($488). The recently introduced
antidepressant sertraline has an annual cost of Rs. 2740
($63.7). Prophylaxis for affective disorders with lithium
therapy would have an annual cost of Rs. 1200 ($27.9).
Regarding antipsychotics, the annual costs of oral medi-
cations of chlorpromazine and haloperidol were the
same, Rs. 2000 ($46.5), long-acting oral penfluridol Rs.
500 ($11.6), and depot long-acting injectable fluphena-
zine decanoate, haloperidol decanoate, and flupenthixol
Rs. 750 ($17.4), Rs. 1500 ($34.9), and Rs. 2100 ($48.8),
respectively. The newer atypical antipsychotics costs
were: resperidone, Rs. 4500 ($104.7) and clozapine Rs.
5500 ($127.9). Benzodiazepines have an annual cost of
$7.5 for diazepam, $3.5 for lorazepam and chlordiazep-
oxide, $2.8 for oxazepam, and $17.6 for alprazolam.
Sleep medications nitrazepam, flurazepam and zopiclone
have an annual cost of $3.3, $8, and $18.8 respectively.
CONCLUSION: The annual costs are amazingly less
than those in Western nations, but nevertheless produce a
significant burden on Indian families, and are a common
reason for poor compliance. Another trend noted above
is that newer antidepressants such as amineptine and
tianeptine, antipsychotics such as resperidone and clozap-
ine, and hypnotics such as zopiclone are much more ex-
pensive than the older medications. Thus, the annual
costs of medications are only likely to increase with time,
enhancing the financial burden of treating these psychiat-
ric disorders.
PMH2
CLINICAL AND ECONOMIC 
CHARACTERIZATION OF FAMILY
MEDICINE PATIENTS RECEIVING 
ANTIDEPRESSANT DRUGS
Taylor AT1, Wagner PJ2, Ahmed A1
1University of Georgia College of Pharmacy, Athens, GA, US; 
2Medical College of Georgia School of Medicine, Augusta, 
GA, US
Many antidepressant drugs are prescribed by generalist
physicians. However, few details are available concerning
the circumstances in which these drugs are utilized in pri-
mary care settings.
Cost $ (1997 year) CT ST P value
Level I 103.0  41.0 14.9  13.2 0.001
Level II 275.3  118.1 189.9  99.1 0.001
Level III 172.2  96.9 175.5  99.6 0.904
